New data from Eli Lilly shows that its drug Zepbound (tirzepatide), originally designed to treat obesity, may also help psoriatic arthritis.[7][8] It is a drug from the group of GLP‑1 agonists, which was administered in the study in addition to an already established immunological drug in patients with psoriatic arthritis.[7][8] Combining Zepbound with an immunological drug led to a reduction in the symptoms of psoriatic arthritis, thus improving the symptoms of the joint disease.[7][8] The study aimed to assess the efficacy of adding tirzepatide to ixekizumab treatment in routine clinical practice.[8] According to the available description of the study, it was about monitoring the effectiveness and safety of this combination, but the detailed numerical results are not summarized in the article.[7][8] Published information suggests a potential benefit of GLP‑1 treatment for patients with psoriatic arthritis, but additional data and detailed results have not yet been specified in the article.[7][8]